SHENZHEN, CHINA, Aug 19, 2025 – (ACN Newswire via SeaPRwire.com) – On 18 August, China Medical System Holdings Limited (“CMS” or the “Company”) announced its interim results for the six months ended 30 June 2025 (the “Reporting Period”), with both revenue and profit recording year-on-year growth, demonstrating the initial results of its strategic transformation. During the Reporting Period, the Company recorded revenue of approximately RMB4.00 billion, representing a year-on-year increase of 10.8%. In the case that all medicines were directly sold by the Company, revenue would be approximately RMB4.67 billion, up 8.9% year-on-year. Net profit was approximately RMB0.93 billion, representing an increase of 3.1% year-on-year. The results reflect that CMS has emerged from the shadow of National Volume-based Procurement (“National VBP”), and its performance is expected to return to a sustainable growth trajectory. Revenue from the Company’s key non-National VBP exclusive/branded products and innovative products (in the case that all medicines were directly sold by the Company) reached approximately RMB2.90 billion, up 20.6% year-on-year, accounting for 62.1% of total revenue. The company’s exclusive/branded products and innovative products have a favorable competitive landscape and high visibility of future growth, and have now become the main drivers of performance growth. According to the interim results announcement, the company has been planning its “New CMS” blueprint since 2018, anchored on the three strategic pillars of “product innovation, commercial model reform, and international expansion” to build a sustainable second growth curve. By the first half of 2025, solid operating results and the steady delivery of innovation outcomes have confirmed that the Company’s strategic upgrade has been gradually translated into tangible achievements. “New Products” Strategy Drives Innovation Value Realization and Solidifies Growth Momentum At the forefront of the Company’s three strategic pillars, the “product innovation” strategy leverages a three-dimensional innovation mechanism of “overseas licensing, domestic collaboration, and in-house R&D” to continuously inject high-value short-, medium- and long-term pipelines, serving as a key growth engine. Currently, the innovation strategy has entered a period of continuous harvest, with new products continuously releasing commercial and clinical value. To date, the Company has successfully commercialized five innovative drugs in China; By 2025, two innovative products — ruxolitinib cream and Desidustat Tablets—are also expected to receive marketing approvals. Ruxolitinib cream is the first and only topical JAK inhibitor approved by the U.S. FDA and the European Medicines Agency for repigmentation in non-segmental vitiligo, and is expected to become the first approved treatment for vitiligo in China, filling a market gap and bringing new hope to Chinese vitiligo patients. Additionally, the New Drug Application (NDA) for the Alzheimer’s disease drug ZUNVEYL in China was accepted in July this year; the consumer healthcare product Poly-L-lactic Acid Microparticle Filler Injection has been approved for marketing, further enriching the Company’s diversified product portfolio. Among the innovative pipeline under R&D, several blockbuster candidates have entered the late-stage clinical development in China and are expected to be commercialized within the next one to three years, forming a new driving force for sustained growth. Among these, the collaborative product Y-3 for Injection has completed Phase III clinical trials in China. This product is an original unimolecular Class 1 innovative drug and the only non-peptide PSD95/nNOS uncoupler that has entered clinical development, with potential to become the first dual-function brain cytoprotectant for treating ischemic stroke while preventing post-stroke depression and anxiety. Another oral small molecule Class 1 innovative drug, ABP-671 (a URAT1 inhibitor) for the treatment of gout and hyperuricemia, is progressing through Phase IIb/III clinical trials in China. Compared with existing mainstream drugs, ABP-671 has the potential to reduce uric acid to lower levels at lower doses and possesses gout-tophus dissolution capability, thereby offering patients a more effective and safer treatment option. CMS continues to expand its innovative pipeline and enhance its end-to-end innovation capabilities to ensure the steady, phased marketing approval of innovative products. In H1 2025, two new collaborative R&D innovative products — ZUNVEYL and MG-K10 (a long-acting anti-IL-4Rα humanized monoclonal antibody injection) — were added to the portfolio. To date, the Company has deployed about 40 differentiated innovative pipeline products, including approximately 20 in-house R&D projects. Advancing “New Models” and “New Markets” Strategies to Unlock Multi-dimensional Growth According to the interim results announcement, CMS continues to advance its “New Models — Commercial Model Reform” strategy, forging anti-cyclical resilience through a diversified ecosystem. It also firmly implements its “New Markets – International Expansion” strategy, building a multi-dimensional growth framework via an industrial internationalization model. Under the commercial model reform strategy, the Company continues to focus on specialty therapeutic fields while expanding into new retail and new media channels, building a comprehensive marketing and promotion system that covers both “in-hospital + out-of-hospital” and “online + offline” channels, and reinforcing its diversified product portfolio with consumer attributes. Its skin health business, Dermavon, has demonstrated strong potential in this particular segment with consumer attributes. Since its independent operation in 2021, Dermavon has achieved dual leadership in both the “coverage of dermatology indications” and the “revenue scale of dermatological prescription drugs”, and is proposed to be spun off and separately listed on the Main Board of the Hong Kong Stock Exchange by way of introduction and distribution in specie, to further unlock its standalone value and high-growth potential. In terms of internationalization, CMS successfully completed its secondary listing on the Main Board of the Singapore Exchange by way of introduction on 15 July 2025, marking a new milestone in its “industrial internationalization” strategy. With Singapore as a hub, the Company has established a comprehensive business system covering the entire value chain of “R&D–Manufacturing–Commercialization” for emerging markets. To date, its commercial platform company, Rxilient, has cumulatively submitted nearly 20 registration applications for pharmaceutical products and medical devices across Southeast Asia, the Middle East, Hong Kong, Macau, and Taiwan Region, covering therapeutic fields such as dermatology, ophthalmology, oncology, autoimmune, and central nervous system. Ruxolitinib cream (vitiligo indication) has been approved for marketing in Macau and Hong Kong, and its registration applications have been submitted in Singapore and Taiwan Region. Intravenous Toripalimab (the first China-originated anti-PD-1 monoclonal antibody drug that has been approved by the China NMPA and the U.S. FDA) has been submitted for registration in five countries, including Malaysia. Tildrakizumab Injection and Sucroferric Oxyhydroxide Chewable Tablets have also been approved for marketing in Hong Kong. Meanwhile, PharmaGend, an associate CDMO manufacturing facility in which CMS holds a 45.0% equity interest, now has an annual production capacity of 1 billion units of oral solid dosage forms (tablets and capsules), and has obtained a drug manufacturing license from Singapore’s HSA, U.S. FDA cGMP certification, and passed Swiss QP audits. The construction of new production lines for nasal sprays, creams, and injectables is progressing steadily, providing high-standard production and delivery capabilities for the international market. Looking ahead, the growth logic of “New CMS” is expected to accelerate its realization, with profitability and performance resilience improving simultaneously. The Company is building a growth framework centered on differentiated innovation, driven by a synergistic and diversified ecosystem, and underpinned by an international footprint. This will open up long-term opportunities for high-quality development, deliver quality pharmaceutical products and services to patients worldwide, and generate sustainable returns for shareholders. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries, strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology/ophthalmology/ skin health businesses. Among them, the skin health business has become a leading enterprise in its field, bringing economies of scale in specialty therapeutic fields. Meanwhile, CMS continuously deepens its business development in the Southeast Asia and Middle East regions, further escorting the sustainable and healthy development. CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Source: China Medical System Holdings Ltd. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com Categories: ACN Newswire
冠君產業信託公佈2025年度中期業績
- 朗豪坊商場開業20周年「立足本地，引領全球潮流文化」，成品牌進駐熱點，Chiikawa拉麵首間海外分店掀熱潮- 花園道三號於2025年到期的租約已全部處理，續約率維持在高水平- 朗豪坊辦公樓推出結合六大健康維度「6D Wellness」的創新概念，強化其一站式身心健康及生活時尚總匯的市場定位- 香港銀行同業拆息下降節省利息開支，2025年債務成功全額再融資香港，2025年8月19日 - (亞太商訊 via SeaPRwire.com) - 持有花園道三號及朗豪坊物業的冠君產業信託（股份代號：2778）公布截至 2025 年 6 月 30 日止的中期業績。業績摘要 2025上半年2024上半年變動租金收益總額 （百萬港元）1,0291,115- 7.6%物業收益淨額（百萬港元）859954- 10.0%可分派收入（百萬港元）476544- 12.6% 每基金單位分派（港元）0.07010.0809- 13.3% 於2025年6月30日於2024年12月31日變動物業組合總值（百萬港元）58,09860,104- 3.3%每基金單位資產淨值（港元）6.797.16- 5.2%資產負債比率24.5%23.7%+ 0.8pp概覽2025年上半年，儘管全球經濟因貿易緊張局勢和地緣政治衝突而面對重重阻力，但香港的市場氣氛獲多項利好因素支持。股市回暖、香港銀行同業拆息於第二季回落，住宅銷售趨穩定，以及旅遊業穩步復蘇均有助抗衡外部壓力。然而，港人外遊熱潮未退，消費力外移令本地零售市道受壓。與此同時，寫字樓租賃市場依然淡靜，反映供求持續失衡。在此市況下，本信託的可分派收入下跌12.6%至4.76億港元，而每基金單位分派（「每基金單位分派」）則減少13.3%至0.0701港元。冠君產業信託行政總裁侯迅女士（左），冠君產業信託投資及投資者關係總監陸嘉萍女士（右）花園道三號雖然中環整體寫字樓市場的租賃動力仍然疲弱，但隨着金融市場轉趨活躍，我們接到的租賃查詢有所增加，需求主要來自金融相關企業。花園道三號落實引進一批新的租賃面積較小的租戶，包括家族辦公室；而一名現有銀行業租戶亦於物業內擴充。於2025年6月30日，花園道三號寫字樓的出租率為80.7%。該物業的租金收益期內減少5.4%至5.40億港元（2024年：5.71億港元）。我們持續推動續租工作，2025年到期的租約已全部處理完畢且續約率維持在高水平，當中包括多名主要租戶的續租。而2026年到期的租約亦有超過70%已續租。朗豪坊辦公樓報告期內，朗豪坊辦公樓推出名為「6D Wellness」的YouTube頻道，藉此強化朗豪坊辦公樓作為一站式身心健康及生活時尚總匯的市場定位。於2025年6月30日，在該物業的租戶組合中，生活時尚（身心健康）行業租戶佔比達68%。於2025年6月30日，朗豪坊辦公樓的出租率保持在86.9%的穩定水平。我們擴大了共享工作空間的營運規模並增設「Social Wellness Hall」，專為舉辦工作坊及交流活動而設，正好呼應辦公樓推廣身心健康的定位。市場租金繼續面對挑戰，租金收益因而減少9.1%至1.51億港元（2024年：1.66億港元）。冠君產業信託行政總裁侯迅女士朗豪坊商場今年迎接開業20周年的朗豪坊商場，繼續秉持「Stay Local，Trend Global」（「立足本地，引領全球潮流文化」）的願景。透過沉浸式體驗和限定商品，我們成功吸引破紀錄的人潮及推動銷售，並在八月刷新單日人流紀錄。近日，首次進軍香港的時裝品牌BENLAI，以及全城首家以生活風格為主題的期間限定店Umbro均在朗豪坊商場開業，人氣拉麵店Chiikawa Ramen Buta亦選址朗豪坊商場設立首家海外分店，旋即成為高人氣新熱點。於2025年6月30日，商場的出租率維持在99.2%的高水平，目前屬已承諾悉數租出的狀態。消費行為的改變為租戶帶來挑戰，租金收益跌至3.38億港元（2024年：3.78億港元）。分派本信託期內可分派收入下跌12.6% 至4.76億港元（2024年：5.44億港元），而每基金單位分派則減少13.3%至0.0701港元（2024年：0.0809港元）。按2025年6月30日的基金單位收市價2.08港元計算，相當於年度分派率6.7%。資產值於2025年6月30 日，本信託旗下物業組合的估值為581億港元，較2024年12月31日的601億港元減少3.3%。可持續發展我們繼續透過提升氣候抗禦力、建立有意義的聯繫及促進社區福祉，為我們的生態圈創造共享價值。報告期內，花園道三號引入人工智能製冷機組優化系統，全年節省大廈制冷設備的能源用量達6.1%。我們透過「綠『惜』環保約章」計劃，推動寫字樓和零售租戶攜手實現可量化的環保目標。此外，我們舉辦以「創新．啟發．融合」為主題的「冠君產業信託 ESG Gala」，凝聚逾千名租戶和商業夥伴，共同推進可持續營運及共融舉措。展望儘管香港零售業已重拾增長，金融市場亦見反彈，預料本信託於2025年後續期間的整體經營環境依然嚴峻。雖然港元利率回落有助節省利息支出，但續租租金下跌或將持續壓抑租金收益及令分派較去年為低。面對競爭激烈的市場環境，我們將繼續以靈活的營運策略積極應對。有關冠君產業信託(股份代號：2778)冠君產業信託擁有及投資提供租金收入的寫字樓及零售物業。信託主要投資位於優越地點的甲級商用物業。現時擁有花園道三號及朗豪坊兩幢位於香港的地標性物業，並以合資股權形式擁有位於倫敦市中心的 66 Shoe Lane，總樓面面積約300萬平方呎，讓投資者可直接投資於優質甲級寫字樓及零售物業。信託自2023年榮獲全球房地產GRESB可持續的最高五星級別。冠君產業信託管理人乃鷹君資產管理（冠君）有限公司，為鷹君集團的成員。網站: www.championreit.com Copyright 2025 亞太商訊 via SeaPRwire.com.
盈立集團積極擴張 開設12間分行 紮根香港新加坡 服務全球投資者
香港，2025年8月19日 - (亞太商訊 via SeaPRwire.com) - 由周大福控股戰略入股的uSMART盈立證券欣然宣佈香港落馬洲港鐵站、西九龍高鐵站分行已正式投入服務，涵蓋陸路出入境和高鐵樞紐客戶群。為隆重其事，盈立證券今日在西九龍分行舉行簡單而隆重的開幕儀式，並邀得不少財經界精英出席，令活動生色不少。開幕禮上，盈立證券執行董事李建翰先生 (Neo Lee) 表示：「為提供更便捷的金融服務予區內居民，盈立集團計劃年內於香港及新加坡兩地社區內開設分行，連同總部客戶專區，服務點增至12個，進駐尖沙咀、銅鑼灣、荃灣、上水及上環等核心地區，全面強化區域服務網絡，拉近與本地客戶的距離，提供更貼心的服務。」「作為港資科技券商No.1^，全球超過800,000用戶，盈立證券十分重視提升用戶的投資體驗，是次開立分行不但提供綜合服務，包括投資諮詢、辦理開戶等，還協助長者及初學者處理開戶流程、學習App使用方法等，藉此深化本地市場，滿足客戶對相關服務的殷切需求。」Neo Lee 續說。(左起︰盈立證券業務拓展總監鄧永麟先生、盈立證券香港市場部總監黃曉霖小姐、盈立證券執行董事兼機構業務負責人李建翰先生、盈立證券資產管理兼投研部總監蔣雄先生及盈立證券業務拓展經理林向尊先生)新張期內，前往分行打卡即可獲贈神秘禮品乙份，同時亦可免費享用飲料及手機充電服務，於分行開戶更可額外獲得豐富禮品。為進一步開拓香港市場，盈立證券推出「Trader賬戶」，香港本地客戶專享美港股一世免佣，美股期權0佣優惠。為感謝客戶的支持，uSMART盈立證券亦同時提供多項真全免優惠，不論新客戶或現有客戶，均可享受，絕無取巧，優惠包括：1)IPO 孖展認購0息│現金認購0手續費；2)>100隻港股ETF 0佣0平台費 (當中包括近期投資者熱愛的高息股ETF、虛擬資產相關ETF及指數ETF等)；3)月供美股、港股0佣0平台費0存倉費及免代收股息稅以上優惠旨在滿足短線、中線及長線投資策略，讓持有uSMART盈立證券賬戶的客戶均能受惠。Neo Lee在開幕禮上透露，集團正積極增聘人手，擴充香港及新加坡團隊，以支持及推進業務發展，提高本地市場競爭力；而集團旗下的美國辦公室亦正式進駐至世界金融中心-紐約曼哈頓城中心，並將專注於對接對沖基金、家族辦公室及擬赴美上市企業，提供機構經紀、資產配置及投行諮詢等專業服務，鞏固全球金融科技券商領域的領先地位。展望未來，uSMART盈立證券秉持以客為本的理念，為更多本地投資者提供星級投資體驗及優質線下服務，同時亦致力推動金融服務的創新與升級，為全球客戶創造更多價值。^「港資科技券商No.1」是取自捷利金融雲截至2025年5月為止連續超過一年數據， uSMART 盈立證券為香港本地港資互聯網券商月成交總額排行第1。 優惠受條件及細則約束關於uSMART盈立證券：由周大福控股戰略入股的盈立證券是一間領先科技港資券商，成立於2018年，7年來憑藉卓越的戰略規劃和創新能力，致力於將科技與金融深度融合，業務範圍涵蓋證券、資產管理、財富管理等領域，為全球投資者獨家研發了金融證券交易平台uSMART HK APP和uSMART SG APP，分別由盈立證券（香港）和盈立證券（新加坡）提供服務。集團APP支持港股、美股、A股（滬深港通）、新加坡股票、日本股票、英國股票、美股期權、ETF、基金、債券、資管、結構化票據、期貨、加密貨幣、貴金屬、黃金和外匯等多元化的投資交易服務，此外更為超高淨值個人與家族、企業提供度身訂制服務，打造全方位綜合性資產管理解決方案。詳情可瀏覽https://hk.usmartglobal.com/傳媒查詢：黃曉霖Carrie Wong9788 4665carriewong@usmart.hk Copyright 2025 亞太商訊 via SeaPRwire.com.
康哲藥業（867.HK，8A8.SG）上半年營收淨利雙升 戰略轉型跑出增長新動能
深圳，2025年8月19日 - (亞太商訊 via SeaPRwire.com) - 8月18日，康哲藥業發佈2025年中期業績，公司營收和利潤同比均實現增長，戰略轉型成效初顯。報告期內，公司實現營業收入約40.0億元（人民幣，下同），同比增長10.8%。若全按藥品銷售收入計算則營收約46.7億元，同比增長8.9%。實現淨利潤約9.3億元，同比增長3.1%。具體來看，康哲藥業已走出國採陰霾，業績將回歸持續上升軌道。公司主要非國採獨家/品牌產品及創新產品全按藥品銷售收入合計約29.0億元，同比增長20.6%，占總收入比重升至62.1%。公司獨家/品牌產品、創新產品競爭格局良好、增長可預期性強，目前已成為拉動業績向上的主力軍。根據業績公告，公司自2018年起擘畫「新康哲」轉型藍圖，以「產品創新、商業革新、國際拓展」三大戰略為支柱，構建可持續的第二增長曲線。行至2025年上半年，良好的經營業績及創新成果持續落地，證實戰略升級已逐步兌現為硬核戰果。「新產品」戰略推動創新價值兌現 夯實增長後勁立於公司三大戰略之首的「產品創新」戰略，依託「海外授權+國內合作+自主研發」三維創新機制，持續注入高價值短、中、長期管線，成為驅動增長的重要引擎。目前，創新戰略已進入持續收穫期，新產品正不斷釋放商業與臨床價值。截至目前，公司已有5款創新藥成功於中國實現商業化；2025年內，蘆可替尼乳膏和德昔度司他片兩款創新產品亦有望獲批上市。蘆可替尼乳膏是美國FDA以及歐洲EMA批准的首個、也是唯一一個局部JAK抑制劑非節段型白癜風複色產品，有望成為中國獲批上市的首款白癜風治療藥物，將填補市場空白，為中國白癜風患者帶來新希望。此外，阿爾茨海默病新藥ZUNVEYL的中國上市申請(NDA)亦已於今年7月獲受理；消費醫療產品注射用聚左旋乳酸微球填充劑已獲得上市批准，進一步豐富公司多元化產品矩陣。在研創新管線中，已有多款重磅候選藥物進入中國後期臨床開發階段，預計將在未來1-3年內陸續進入商業化，形成持續放量的新動力。其中，合作產品注射用Y-3已完成中國III期臨床，該產品為原創單分子1類新藥，亦為全球唯一進入臨床研究的非肽類PSD95/nNOS解偶聯劑，並有望成為首個治療缺血性卒中並預防卒中後抑鬱焦慮的雙功能腦細胞保護藥物。另一個口服小分子1類新藥ABP-671（URAT1抑制劑）用於治療痛風及高尿酸血症，目前其中國IIb/III期臨床正有序推進中。相較現有主流藥物，該產品有潛力以更低劑量將尿酸降低至更低水平，並具有溶解痛風石的能力，有望為患者提供療效更優、安全性更高的治療選擇。康哲藥業亦持續增厚創新儲備，不斷夯實全鏈條創新實力，以實現創新產品分階段、源源不斷獲批上市。2025上半年，公司新增ZUNVEYL、MG-K10（長效抗IL-4Rα人源化單抗注射液）兩款合作開發創新產品。截至目前，公司累計佈局約40款差異化創新管線，其中約20項為自主研發項目。同步推進「新模式」、「新地域」戰略 拓展多維增量空間根據業績公告，康哲藥業持續推進「新模式-商業革新」戰略，以多元生態鍛造抗週期韌性；並堅定執行「新地域-國際拓展」戰略，以產業國際化出海模式構建多維增長格局。在商業革新戰略下，公司持續聚焦專科領域，同時拓展新零售、新媒體渠道，構建「院內+院外」、「線上+線下」全覆蓋的營銷推廣體系，並持續強化消費醫療產品佈局。公司皮膚健康業務「德鎂醫藥」已在這一具消費屬性的賽道嶄露頭角，自2021年獨立運營以來，已實現皮膚疾病領域適應症覆蓋廣度、皮膚處方藥收入規模的雙重領先，將通過介紹上市、實物分派方式，擬分拆於香港聯交所主板獨立上市，進一步釋放其獨立價值與高成長潛力。國際化方面，2025年7月15日，公司以介紹方式成功於新加坡交易所完成第二上市，「產業國際化」戰略邁入新里程。以新加坡為樞紐，公司構建起覆蓋「研-產-銷」的新興市場全鏈條業務體系。截至目前，商業化平台公司Rxilient已在東南亞、中東、港澳台等地區累計提交近20款藥品和器械註冊申請，涵蓋皮膚科、眼科、腫瘤、自免、中樞神經等領域。蘆可替尼乳膏（白癜風適應症）已在澳門、香港獲批，並已遞交新加坡、台灣註冊申請；靜脈注射用特瑞普利單抗（首個被中國NMPA及美國FDA批准上市的國產抗PD-1單抗藥物）已提交馬來西亞等五國註冊申請；替瑞奇珠單抗注射液、蔗糖羥基氧化鐵咀嚼片亦在香港獲批。同時，公司持股45.0%的聯營CDMO生產工廠PharmaGend，目前已具備片劑、膠囊等口服固體製劑年產10億片的能力，並獲得新加坡HSA頒發的生產許可證、美國FDA cGMP認證及瑞士QP審計通過。PharmaGend鼻噴劑、乳膏、注射劑等新產線的建設正穩步推進中，為國際市場提供高標準生產交付能力。展望未來，「新康哲」增長邏輯有望加速兌現，盈利能力與業績韌性將同步提升。公司正構建以差異化創新為核心、多元生態協同驅動、國際化佈局支撐的增長體系，為高質量發展打開長期空間，為全球患者提供高品質醫藥產品和服務，為股東帶來可持續回報。關於康哲藥業康哲藥業是一家鏈接醫藥創新與商業化，把控產品全生命週期管理的開放式平台型企業，致力於提供有競爭力的產品和服務，滿足尚未滿足的醫療需求。康哲藥業專注於全球首創（FIC）及同類最優（BIC）的創新產品，並高效推進創新產品臨床研究開發和商業化進程，賦能科研成果向診療實踐的持續轉化，造福患者。康哲藥業聚焦專科領域，擁有被驗證的商業化能力，廣泛的渠道覆蓋和多疾病領域專家資源，核心在售產品已獲領先的學術與市場地位。康哲藥業圍繞優勢專科領域不斷縱深發展，以鞏固心腦血管/消化/眼科/皮膚健康業務競爭力，其中皮膚健康業務已成爲該細分領域的龍頭企業，帶來專科規模效率。同時，康哲藥業持續深化東南亞及中東區域業務發展，助力高質量持續健康發展。康哲藥業免責與前瞻性聲明本新聞無意向您做任何產品的推廣，非廣告用途。本新聞不對任何藥品和醫療器械和/或適應症作推薦。若您想瞭解具體疾病診療資訊，請遵從醫生或其他醫療衛生專業人士的意見或指導。醫療衛生專業人士作出的任何與治療有關的決定應根據患者的具體情況並遵照藥品說明書。由康哲藥業編制的此新聞不構成購買或認購任何證券的任何要約或邀請，不形成任何合約或任何其他約束性承諾的依據或加以依賴。本新聞由康哲藥業根據其認為可靠之資料及數據編制，但康哲藥業並無進行任何說明或保證、明述或暗示，或其他表述，對本新聞內容的真實性、準確性、完整性、公平性及合理性不應加以依賴。本新聞中討論的若干事宜可能包含涉及康哲藥業的市場機會及業務前景的陳述，該等陳述分別或統稱為前瞻性聲明。該等前瞻性聲明並非對未來表現的保證，存在已知及未知的風險、不明朗性及難以預知的假設。康哲藥業並不採納本新聞包含的第三方所做的任何前瞻性聲明及預測，康哲藥業對該等第三方聲明及預測不承擔責任。 Copyright 2025 亞太商訊 via SeaPRwire.com.
昌迪加爾最佳搬家公司
(SeaPRwire) - Sharma Cargo Movers and Packers – 值得信賴的搬遷合作夥伴印度昌迪加爾 2025年8月19日 - Sharma Cargo Movers and Packers：昌迪加爾最值得信賴的搬家公司，提供無縫搬遷服務 搬遷通常被認為是人生中最有壓力的事件之一。從打包易碎的家居物品到運輸大型家具，再到處理物流，整個過程往往費力且壓力重重。這就是專業搬家公司發揮關鍵作用的地方。在眾多服務供應商中，勤奮的 Sharma Cargo Movers and Packers 已建立起作為最值得信賴且及時的服務供應商之一的良好聲譽 提供無憂搬家服務 的宗旨是為客戶提供順暢、高效且無壓力的搬遷服務。憑藉多年在家庭搬遷、辦公室搬遷、車輛運輸和倉儲服務方面的專業知識，該公司已成為昌迪加爾及周邊地區家庭和企業的首選。 我們訓練有素的專業團隊確保每一件物品，無論是易碎的玻璃器皿還是沉重的家具，都得到最細心的打包和運輸。我們使用高品質的包裝材料和現代化設備，確保物品在運輸過程中完好無損並準時送達。 為何選擇昌迪加爾的 Sharma Cargo Movers and Packers 專業知識和經驗：憑藉全面的行業知識，我們理解搬家所面臨的挑戰，並提供客製化解決方案。 安全可靠的服務：從打包到卸貨，安全是我們的首要任務。 價格實惠：透明的價格，絕無隱藏費用。 廣泛的服務網絡：涵蓋昌迪加爾市內搬遷和印度各地長途搬遷。 以客戶為中心：提供個人化服務和24/7客戶支援。 追求卓越 Sharma Cargo Movers and Packers 脫穎而出的原因在於我們對客戶滿意度的堅定承諾。與許多服務供應商不同，我們將每次搬遷都視為獨特的項目。我們的專業人員精心策劃每項工作，確保客戶能夠安心無憂。我們負責繁重的工作。 我們也提供專業的車輛運輸服務，確保汽車和摩托車安全送達目的地。此外，我們的倉儲設施專為需要臨時或長期儲存的客戶而設。 昌迪加爾值得信賴的搬家公司 多年來，我們已成功處理了昌迪加爾無數的住宅和商業搬遷，贏得了客戶的信任和回頭客。客戶的熱情好評和推薦不勝枚舉，這些都證明了我們服務的品質。 無論您是市內搬遷、遷往不同邦，還是搬遷您的辦公設備，Sharma Cargo Movers and Packers 都是您可以絕對信賴的名稱。我們的目標是讓您的搬家旅程比以往任何時候都更容易、更快、更可靠。 關於 Sharma Cargo Movers and Packers Sharma Cargo Movers and Packers 是一家專業搬遷公司，在印度各地提供端到端的包裝和搬家服務。總部位於昌迪加爾，該公司專精於家庭搬遷、辦公室搬遷、車輛運輸、倉儲和物流。以安全、實惠和可靠著稱，我們致力於提供根據客戶需求量身定制的無與倫比的搬遷解決方案。 欲了解更多資訊或預訂服務，請立即訪問我們，了解為何我們被公認為昌迪加爾最值得信賴的搬家公司。 搬家或搬辦公室？是的，那很麻煩。但有了合適的團隊協助，事情就會順利得多。Sharma Cargo 已在這裡建立起作為首選搬家服務之一的聲譽。他們對如何在不費吹灰之力地搬運物品方面很在行。 這些人經驗豐富。在各種搬遷方面有多年經驗—家庭物品、辦公室搬遷，甚至汽車和摩托車。他們的團隊處理從打包箱子到安全儲存物品的一切。不趕時間，不草率。只有細心的處理，確保您的物品完好無損、準時送達。 是什麼讓他們脫穎而出？他們使用頂級的包裝材料和真正好用的設備。不是你看到一些地方使用的那些脆弱的箱子或破損的手推車。昌迪加爾市內搬遷還是跨國運輸？沒關係。他們在不掏空你錢包的情況下保持可靠性。 他們明白。每一次搬遷都不同，無論是家庭住宅還是公司辦公室設置。這就是為什麼他們專注於預先弄清楚你確切的需求。這裡沒有一刀切的計畫。將專業技能與實際關懷結合起來，這就是他們成為該地區任何尋找靠譜搬家公司的人的首選。 考慮搬家嗎？如果你想一路無憂無慮，這些人是你的不二之選。安全第一，流程順暢有保證。媒體聯絡Sharma Cargo Movers and Packers7527865551Shop No - 1252 Saini Vihar Phase-3, Baltana, Zirakhpur 來源：packers and movers 本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈，覆蓋超過6,500個媒體庫、86,000名編輯和記者，以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。
Ksquare Energy：古吉拉特邦最值得信賴的太陽能電池板公司，引領業界
(SeaPRwire) - 古吉拉特邦擁有超過300個晴天，是太陽能的熱點。Ksquare Energy作為該邦的第一屋頂太陽能品牌，提供MNRE認證的面板、端到端服務、融資和補貼支持，使家庭、企業和工業都能負擔得起太陽能。艾哈邁達巴德，古吉拉特邦，2025年8月19日 - 太陽能不再是一種短暫的趨勢——它是一種生活方式。古吉拉特邦每年有超過300個晴天，是推廣太陽能的理想邦。對於艾哈邁達巴德的房主來說，安裝太陽能意味著更低的能源成本和長期的可持續性。 但在古吉拉特邦眾多的太陽能公司中，您該如何選擇合適的一家呢？答案在於信任、技術和總體價值——這正是Ksquare Energy，被譽為 古吉拉特邦第一屋頂太陽能品牌，所擅長之處。 Ksquare Energy 的獨特之處在於： 可靠性與聲譽：在古吉拉特邦各地成功安裝了數千個屋頂太陽能系統。 端到端解決方案：從諮詢到設計、安裝和售後服務。 智慧技術：物聯網驅動的監控、高效面板和先進逆變器。 認證品質：MNRE 和 BIS 批准的產品確保符合補貼資格。 負擔得起的融資：彈性的分期付款（EMI）和補貼支持，讓太陽能觸手可及。 強大的支援網絡：在古吉拉特邦各地設有專門團隊，提供快速服務和年度維護合約（AMC）。 Ksquare Energy 將尖端太陽能技術與無與倫比的客戶支援相結合，賦予家庭、企業和工業信心擁抱清潔能源。 選擇太陽能就是選擇節省、永續性和安全性。有了 作為您的太陽能合作夥伴，您不僅僅是安裝面板——您是在投資一個更綠色、更光明的未來。媒體聯絡Ksquare Energy Pvt. Ltd.7227931919B-403/404 Signature - 2 Sarkhej Sanand Road, Sarkhej 來源：https://www.ksquareenergy.com/residential-solar-rooftop-ahmedabad本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈，覆蓋超過6,500個媒體庫、86,000名編輯和記者，以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。
PremiumCAD 慶祝 德拉敦 全新最先進辦公室 盛大開幕
(SeaPRwire) - 諾伊達，北方邦 2025年8月19日 - PremiumCAD，一家領先的太陽能光伏設計與工程解決方案供應商，榮幸地宣布其位於台拉登的新辦公室盛大開幕。此次擴張標誌著該公司成長歷程中的一個重要里程碑，也展現了其致力於為團隊營造一個鼓舞人心且富有成效的工作場所的承諾。 新辦公室位於台拉登市中心，展示了現代品牌形象、充滿活力且寬敞的佈局，以及旨在激發創造力和協作的環境。該設施反映了 PremiumCAD 將創新與員工福祉相結合的願景，打造一個讓人才蓬勃發展的工作場所。 該辦公室設有高級設施和專屬休閒空間，為員工提供工作與放鬆之間的完美平衡。從設計精美的公共區域到協作工作站和休閒區，這個空間都經過精心規劃，旨在促進生產力、舒適度並建立強大的團隊文化。 「台拉登的新辦公室不僅僅代表著一次擴張——它反映了我們致力於建立一個讓員工感到受到啟發和重視的世界級工作場所的承諾，」PremiumCAD 共同所有人 Ratan Singh 表示。「我們相信一個優越的工作環境能夠推動創新，而這個辦公室證明了我們對客戶和員工的奉獻。」 憑藉其策略性地理位置和鼓舞人心的內部設計，台拉登辦公室將成為人才發展、協作專案以及為全球客戶提供尖端太陽能工程解決方案的中心。 關於 PremiumCAD PremiumCAD 是太陽能光伏設計與工程服務領域的領先者，專注於為住宅、商業和公用事業規模的太陽能專案提供高品質解決方案。PremiumCAD 專注於精準、效率和創新，賦能全球太陽能公司加速專案時程並優化能源生產。 媒體洽詢，請聯繫： Ratan Singh 共同所有人兼董事 PremiumCAD 電子郵件：ratan.s@premiumCAD.com| 電話：+1 (801) 901 3075 網站： 媒體聯絡PremiumCAD Solar LLPAce Studio, Plot No. 01B, 5th Floor, Sector 126,來源：Premiumcad本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈，覆蓋超過6,500個媒體庫、86,000名編輯和記者，以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。
Stevron Tools 推出先進工業工具，以 Bonhoeffer Machines 的全球專業為後盾
(SeaPRwire) - 透過卓越的工程技術，為全球各產業提供精準、耐用和創新的解決方案。2025年8月19日，哈里亞納邦古爾岡 - Stevron Tools，工業解決方案領域的信賴品牌，自豪地宣布擴展其先進工具系列，旨在滿足全球產業日益增長的需求。作為工程和機械領域的公認領導者Bonhoeffer Machines () 的一部分，Stevron Tools 將國際專業知識與創新相結合，提供代表可靠性、性能和長期價值的工具。 Stevron Tools 專注於服務製造、建築、汽車和航空航天領域，致力於設計和供應不僅能承受最嚴苛工作條件，還能提升效率和安全標準的工具。每項產品都凝聚了多年的研究、技術進步和實務產業知識。 Stevron Tools 的新一代工具在設計時充分考量了耐用性和精準性，確保各產業在日常運營中能順暢依賴它們。藉由Bonhoeffer Machines 的技術實力和全球影響力，Stevron Tools 得以向全球各產業提供更智能、更永續且更具成本效益的解決方案。 「在 Stevron Tools，我們深知企業在生產力和安全方面不容妥協，」一位公司發言人表示。「成為 Bonhoeffer Machines 的一部分，使我們能夠將全球創新融入我們設計的每一件產品中，確保我們的客戶能夠獲得最好的工具，幫助他們實現卓越運營。」 Stevron Tools 和 Bonhoeffer Machines 之間的合作夥伴關係為持續創新、強化客戶支援和全球分銷通路開啟了機會。兩家公司正攜手共建一個未來，讓工業工具更智能、更高效，並能適應現代技術變革，包括自動化和永續製造實踐。 關於 Stevron Tools Stevron Tools () 專注於開發精密工程工業工具，這些工具能夠承受最嚴苛的條件。憑藉對品質、創新和客戶滿意度的堅定承諾，Stevron Tools 繼續成為全球企業可靠的合作夥伴。 關於 Bonhoeffer Machines Bonhoeffer Machines () 是先進工程和工業機械解決方案領域的全球領導者。Bonhoeffer Machines 以創新和卓越技術而聞名，為各行各業提供尖端產品、服務和長期價值創造。 聯絡資訊 地點：印度古爾岡電子郵件：info@stevrontools.com電話：+91 98195 06816網站： 媒體聯絡Stevron Tools 98195 06816 來源：Stevron Tools本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈，覆蓋超過6,500個媒體庫、86,000名編輯和記者，以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。
Waymond Wesley II：平衡正義與廚藝熱情
(SeaPRwire) - Waymond Wesley II，律師兼 Chef Way，融合正義和烹飪熱情，在他旅程的每一步都激勵著韌性、成長和創造力。德克薩斯州休斯頓 2025 年 8 月 19 日 - Waymond Wesley II，律師兼 Chef Way，融合正義和烹飪熱情，在他旅程的每一步都激勵著韌性、成長和創造力。 平衡兩個備受矚目的世界絕非易事，但在網路上被稱為 Chef Way 的他，做到了。他成功地開闢了一條道路，將他對公共服務的承諾與他對烹飪創造力的熱情聯繫起來，證明一個人的身份可以是複雜且具有深刻影響力的。作為一個對維護社區的法律和秩序負有重大責任的人，以及一個對食物有無盡熱情的人，至少可以說，他令人難以置信。 一位卓越的個人 Wesley 在法律體系內建立了令人稱讚的職業生涯，目前擔任商業訴訟律師。 在這個角色中，他以專業和目標為追求正義做出貢獻。 他的工作反映了對公平、法律誠信和社區倡導的堅定信念。 他對法治的奉獻超越了技術專業知識，植根於為社會做出有意義貢獻的真誠願望。 除了他的法律責任之外，Wesley 也在數位食品領域聲名鵲起。 以 Chef Way 的名義，他在 Instagram 和 YouTube 等平台上獲得了忠實的追隨者。 他視覺豐富、風味濃郁的菜餚頌揚了大胆的口味和充滿活力的呈現方式，提供了一種獨特的視角，將傳統與創新聯繫起來。 他的烹飪內容與眾不同之處不僅在於食物本身，還在於他為每道食譜帶來的活力、關懷和文化自豪感。 一個關於成長和謙遜的故事 使他的故事更深刻的是成長的人性元素。 Wesley 擁抱反思、責任和自我完善，將其視為他旅程的重要組成部分。 在公眾人物經常因挑戰而受到定義的時代，他選擇以真實性、目標和韌性來領導。 透過他的法律和創意平台，他不斷表明問責制和進化可以攜手並進。 Wesley 在律師和美食內容創作者的角色之間轉換的能力不僅僅是展示才華，而且反映了韌性。 它說明了個人不是一維的想法。 他們進化、學習和適應。 透過他的旅程，他已成為那些努力將目標與熱情融合，或尋求透過行動而非言語來獲得救贖的人們產生共鳴的人物。 總結 今天， Waymond Wesley II 繼續發展他的雙重遺產——一個植根於正義，另一個植根於創造力。 無論他是在法庭內還是在廚房櫃檯後，他都以真誠和卓越的態度對待每一項努力。 他的故事證明了第二次機會的力量，並提醒人們，有意義的改變通常始於自我意識和勇氣。 在此處閱讀有關 Waymond Wesley II 的更多資訊： 媒體聯絡Waymond Wesley II Source :Waymond Wesley II本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈，覆蓋超過6,500個媒體庫、86,000名編輯和記者，以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。 ```
Atua AI 推出可擴展的部署引擎，以簡化 Web3 運營
(SeaPRwire) - 全新以自動化為中心的引擎增強了適應性，降低了管理費用，並加速了去中心化企業的整合。華盛頓州西雅圖，2025 年 8 月 19 日 - 宣布推出其可擴展的部署引擎，旨在簡化去中心化 Web3 基礎設施的運營。這些新引擎旨在提高工作流程的可靠性，同時減少企業在尋求將 AI 驅動的自動化整合到區塊鏈環境中時遇到的系統瓶頸。 通過引入適應性框架，Atua AI 使企業能夠更有效地部署應用程式和服務，減少運營延遲，並確保跨鏈的更大靈活性。 這些部署引擎的設計旨在隨著業務需求的變化而擴展，在不影響性能或安全性的情況下支持複雜的工作流程。 新的架構體現了 Atua AI 對於解決去中心化生態系統中挑戰的持續承諾。 可擴展引擎通過將多代理系統與模組化邏輯相結合，提供優化的性能，確保企業在動態 Web3 市場中導航時的實時適應性。 關於 Atua AI Atua AI 在 Web3 領域提供了一套全面的 AI 驅動的生產力和創造力工具。 從智能工作流程自動化到模組化部署系統，該平台旨在加速企業在多個鏈上採用去中心化 AI 解決方案。媒體聯絡KaJ Labs88887012914730 University Way NE 104- #175 Source :KaJ Labs 本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈，覆蓋超過6,500個媒體庫、86,000名編輯和記者，以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。 ```
FurGPT 部署智能同步工具以提升夥伴AI互動
(SeaPRwire) - 本次升級引入了先進的情感和行為同步功能，以實現逼真的數位寵物互動。新加坡，新加坡 2025 年 8 月 19 日 - (FGPT) 這家由AI驅動的伴侶平台，已推出其智能同步工具，旨在提升數位寵物般的互動體驗。這項創新著重於情感對齊和行為真實感，為用戶提供與其AI伴侶更自然、更沉浸的體驗。 通過精進情感線索和適應性互動的同步，FurGPT 讓其AI伴侶能夠以反映真實行為和真誠連結的方式進行回應。此次升級推動了該平台彌合科技與陪伴之間鴻溝的持續使命，為用戶體驗帶來了新的維度。 憑藉這些增強功能，FurGPT 正繼續保持其在伴侶AI領域作為創新者的勢頭。該同步系統實現了更高的一致性、更智能的回應和更高水準的個性化——支持了該平台創建日常生活中情感感知且易於使用的AI解決方案的更廣泛承諾。 關於 FurGPT FurGPT (FGPT) 是一個下一代AI平台，旨在建立情感智能、適應性強的數位伴侶。通過先進的學習模型、個性化的回應和創新的互動系統，FurGPT 增強了用戶與AI驅動的寵物般體驗的連結和互動方式。媒體聯絡KaJ Labs88887012914730 University Way NE 104- #175 來源 :KaJ Labs本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈，覆蓋超過6,500個媒體庫、86,000名編輯和記者，以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。
CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers
SHENZHEN, CHINA, Aug 19, 2025 – (ACN Newswire via SeaPRwire.com) – On 18 August, China Medical System Holdings Limited (“CMS” or the “Company”) announced its interim results for the six months ended 30 June 2025 (the “Reporting Period”), with both revenue and profit recording year-on-year growth, demonstrating the initial results of its strategic transformation. During the Reporting Period, the Company recorded revenue of approximately RMB4.00 billion, representing a year-on-year increase of 10.8%. In the case that all medicines were directly sold by the Company, revenue would be approximately RMB4.67 billion, up 8.9% year-on-year. Net profit was approximately RMB0.93 billion, representing an increase of 3.1% year-on-year. The results reflect that CMS has emerged from the shadow of National Volume-based Procurement (“National VBP”), and its performance is expected to return to a sustainable growth trajectory. Revenue from the Company’s key non-National VBP exclusive/branded products and innovative products (in the case that all medicines were directly sold by the Company) reached approximately RMB2.90 billion, up 20.6% year-on-year, accounting for 62.1% of total revenue. The company’s exclusive/branded products and innovative products have a favorable competitive landscape and high visibility of future growth, and have now become the main drivers of performance growth. According to the interim results announcement, the company has been planning its “New CMS” blueprint since 2018, anchored on the three strategic pillars of “product innovation, commercial model reform, and international expansion” to build a sustainable second growth curve. By the first half of 2025, solid operating results and the steady delivery of innovation outcomes have confirmed that the Company’s strategic upgrade has been gradually translated into tangible achievements. “New Products” Strategy Drives Innovation Value Realization and Solidifies Growth Momentum At the forefront of the Company’s three strategic pillars, the “product innovation” strategy leverages a three-dimensional innovation mechanism of “overseas licensing, domestic collaboration, and in-house R&D” to continuously inject high-value short-, medium- and long-term pipelines, serving as a key growth engine. Currently, the innovation strategy has entered a period of continuous harvest, with new products continuously releasing commercial and clinical value. To date, the Company has successfully commercialized five innovative drugs in China; By 2025, two innovative products — ruxolitinib cream and Desidustat Tablets—are also expected to receive marketing approvals. Ruxolitinib cream is the first and only topical JAK inhibitor approved by the U.S. FDA and the European Medicines Agency for repigmentation in non-segmental vitiligo, and is expected to become the first approved treatment for vitiligo in China, filling a market gap and bringing new hope to Chinese vitiligo patients. Additionally, the New Drug Application (NDA) for the Alzheimer’s disease drug ZUNVEYL in China was accepted in July this year; the consumer healthcare product Poly-L-lactic Acid Microparticle Filler Injection has been approved for marketing, further enriching the Company’s diversified product portfolio. Among the innovative pipeline under R&D, several blockbuster candidates have entered the late-stage clinical development in China and are expected to be commercialized within the next one to three years, forming a new driving force for sustained growth. Among these, the collaborative product Y-3 for Injection has completed Phase III clinical trials in China. This product is an original unimolecular Class 1 innovative drug and the only non-peptide PSD95/nNOS uncoupler that has entered clinical development, with potential to become the first dual-function brain cytoprotectant for treating ischemic stroke while preventing post-stroke depression and anxiety. Another oral small molecule Class 1 innovative drug, ABP-671 (a URAT1 inhibitor) for the treatment of gout and hyperuricemia, is progressing through Phase IIb/III clinical trials in China. Compared with existing mainstream drugs, ABP-671 has the potential to reduce uric acid to lower levels at lower doses and possesses gout-tophus dissolution capability, thereby offering patients a more effective and safer treatment option. CMS continues to expand its innovative pipeline and enhance its end-to-end innovation capabilities to ensure the steady, phased marketing approval of innovative products. In H1 2025, two new collaborative R&D innovative products — ZUNVEYL and MG-K10 (a long-acting anti-IL-4Rα humanized monoclonal antibody injection) — were added to the portfolio. To date, the Company has deployed about 40 differentiated innovative pipeline products, including approximately 20 in-house R&D projects. Advancing “New Models” and “New Markets” Strategies to Unlock Multi-dimensional Growth According to the interim results announcement, CMS continues to advance its “New Models — Commercial Model Reform” strategy, forging anti-cyclical resilience through a diversified ecosystem. It also firmly implements its “New Markets – International Expansion” strategy, building a multi-dimensional growth framework via an industrial internationalization model. Under the commercial model reform strategy, the Company continues to focus on specialty therapeutic fields while expanding into new retail and new media channels, building a comprehensive marketing and promotion system that covers both “in-hospital + out-of-hospital” and “online + offline” channels, and reinforcing its diversified product portfolio with consumer attributes. Its skin health business, Dermavon, has demonstrated strong potential in this particular segment with consumer attributes. Since its independent operation in 2021, Dermavon has achieved dual leadership in both the “coverage of dermatology indications” and the “revenue scale of dermatological prescription drugs”, and is proposed to be spun off and separately listed on the Main Board of the Hong Kong Stock Exchange by way of introduction and distribution in specie, to further unlock its standalone value and high-growth potential. In terms of internationalization, CMS successfully completed its secondary listing on the Main Board of the Singapore Exchange by way of introduction on 15 July 2025, marking a new milestone in its “industrial internationalization” strategy. With Singapore as a hub, the Company has established a comprehensive business system covering the entire value chain of “R&D–Manufacturing–Commercialization” for emerging markets. To date, its commercial platform company, Rxilient, has cumulatively submitted nearly 20 registration applications for pharmaceutical products and medical devices across Southeast Asia, the Middle East, Hong Kong, Macau, and Taiwan Region, covering therapeutic fields such as dermatology, ophthalmology, oncology, autoimmune, and central nervous system. Ruxolitinib cream (vitiligo indication) has been approved for marketing in Macau and Hong Kong, and its registration applications have been submitted in Singapore and Taiwan Region. Intravenous Toripalimab (the first China-originated anti-PD-1 monoclonal antibody drug that has been approved by the China NMPA and the U.S. FDA) has been submitted for registration in five countries, including Malaysia. Tildrakizumab Injection and Sucroferric Oxyhydroxide Chewable Tablets have also been approved for marketing in Hong Kong. Meanwhile, PharmaGend, an associate CDMO manufacturing facility in which CMS holds a 45.0% equity interest, now has an annual production capacity of 1 billion units of oral solid dosage forms (tablets and capsules), and has obtained a drug manufacturing license from Singapore’s HSA, U.S. FDA cGMP certification, and passed Swiss QP audits. The construction of new production lines for nasal sprays, creams, and injectables is progressing steadily, providing high-standard production and delivery capabilities for the international market. Looking ahead, the growth logic of “New CMS” is expected to accelerate its realization, with profitability and performance resilience improving simultaneously. The Company is building a growth framework centered on differentiated innovation, driven by a synergistic and diversified ecosystem, and underpinned by an international footprint. This will open up long-term opportunities for high-quality development, deliver quality pharmaceutical products and services to patients worldwide, and generate sustainable returns for shareholders. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries, strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology/ophthalmology/ skin health businesses. Among them, the skin health business has become a leading enterprise in its field, bringing economies of scale in specialty therapeutic fields. Meanwhile, CMS continuously deepens its business development in the Southeast Asia and Middle East regions, further escorting the sustainable and healthy development. CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Source: China Medical System Holdings Ltd. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com Categories: ACN Newswire